RU2130493C1
(ru)
*
|
1984-07-06 |
1999-05-20 |
Новартис Аг |
Способ получения белка с активностью gm-csf приматов
|
US5795568A
(en)
*
|
1984-09-19 |
1998-08-18 |
Novartis Corporation |
Method of treating infectious disease with GM-CSF
|
US5422105A
(en)
*
|
1985-02-05 |
1995-06-06 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor 1
|
US5556620A
(en)
*
|
1985-02-05 |
1996-09-17 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor-1 to enhance wound healing
|
US5837229A
(en)
*
|
1985-02-05 |
1998-11-17 |
Chiron Corporation |
Uses of recombinant colony stimulating factor-1
|
US5104650A
(en)
*
|
1985-02-05 |
1992-04-14 |
Cetus Corporation |
Uses of recombinant colony stimulating factor-1
|
US5093115A
(en)
*
|
1985-06-11 |
1992-03-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of preparing activated killer monocytes for treating colorectal cancer
|
US5391706A
(en)
*
|
1987-07-16 |
1995-02-21 |
Schering Plough Corporation |
Purification of GM-CSF
|
AU638204B2
(en)
*
|
1987-11-12 |
1993-06-24 |
Schering Corporation |
Acceleration of bone formation with gm-csf
|
BE1002141A5
(fr)
*
|
1988-01-13 |
1990-07-31 |
Bartholeyns Jacques |
Procede de culture et d'activation de cellules humaines et conditionnement pour le traitement du cancer.
|
JPH01193227A
(ja)
*
|
1988-01-29 |
1989-08-03 |
Res Dev Corp Of Japan |
癌免疫療法補助剤
|
AU4219689A
(en)
*
|
1988-08-19 |
1990-03-23 |
Genetics Institute Inc. |
Treatment for malignant melanoma
|
GB8824591D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Fractionation process
|
ES2055314T3
(es)
*
|
1989-01-30 |
1994-08-16 |
Schering Corp |
Tratamiento de disfuncion leucocitaria con gm-csf.
|
US5154921A
(en)
*
|
1990-07-13 |
1992-10-13 |
Dana-Farber Cancer Institute, Inc. |
Promotion of maturation of hematopoietic progenitor cells
|
US5199942A
(en)
*
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
US5904920A
(en)
*
|
1991-10-04 |
1999-05-18 |
Whitehead Institute For Biomedical Research |
Regulation of systemic immune responses utilizing cytokines and antigens
|
US5637483A
(en)
*
|
1991-10-04 |
1997-06-10 |
Whitehead Institute For Biomedical Research |
Irradiated tumor cell vaccine engineered to express GM-CSF
|
US5292513A
(en)
*
|
1992-05-18 |
1994-03-08 |
Anthony G. Gristina |
Method for nonspecific cellular immune stimulation
|
US6001351A
(en)
*
|
1993-05-18 |
1999-12-14 |
I.D.M. Immuno-Designed Molecules |
Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
|
JP3454825B2
(ja)
*
|
1993-05-18 |
2003-10-06 |
イ・デ・エム・イミュノ−デジネ・モレキュル |
新規なマクロファージ、その製造方法、及び医薬組成物の活性物質としてのその用途
|
US6103694A
(en)
*
|
1995-07-21 |
2000-08-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of decreasing radiation of radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
|
US5800812A
(en)
*
|
1995-09-15 |
1998-09-01 |
Yeda Research And Development Co. Ltd. |
Methods of use of mononuclear phagocytes to promote axonal regeneration
|
US6267955B1
(en)
|
1995-09-15 |
2001-07-31 |
Yeda Research And Development Co. Ltd. |
Mononuclear phagocytes and their use to promote axonal regeneration
|
US5942253A
(en)
*
|
1995-10-12 |
1999-08-24 |
Immunex Corporation |
Prolonged release of GM-CSF
|
US6080409A
(en)
|
1995-12-28 |
2000-06-27 |
Dendreon Corporation |
Immunostimulatory method
|
US6821516B1
(en)
*
|
1997-07-18 |
2004-11-23 |
I.D.M. Immuno-Designed Molecules |
Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
JP2002529707A
(ja)
*
|
1998-11-03 |
2002-09-10 |
セル ジェネシス インコーポレイテッド |
癌関連抗原およびそれらの同定の方法
|
ATE516046T1
(de)
|
1999-05-13 |
2011-07-15 |
Wyeth Corp |
Adjuvans kombinationsformulierungen
|
US8017590B1
(en)
|
1999-10-22 |
2011-09-13 |
Sanofi Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
SG143058A1
(en)
*
|
2000-08-11 |
2008-06-27 |
Favrille Inc |
Method and composition for altering a t cell mediated pathology
|
US6911204B2
(en)
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
SK5482003A3
(en)
*
|
2000-11-10 |
2004-03-02 |
Wyeth Corp |
Adjuvant combination formulations
|
EP1421098A4
(en)
*
|
2001-04-13 |
2006-03-15 |
Wyeth Corp |
SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
EP2277897A1
(en)
|
2001-04-16 |
2011-01-26 |
Wyeth Holdings Corporation |
Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
IL163988A0
(en)
*
|
2002-03-15 |
2005-12-18 |
Wyeth Corp |
Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7301554B2
(en)
*
|
2002-09-20 |
2007-11-27 |
Ricoh Company, Ltd. |
Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
|
US20040141947A1
(en)
|
2002-10-16 |
2004-07-22 |
Hunter Samuel F. |
Method for treatment of demyelinating central nervous system disease
|
US20040197312A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
US8071652B2
(en)
*
|
2003-08-21 |
2011-12-06 |
The Board Of Regents Of The University Of Texas System |
Method of treating irritable bowel syndrome
|
EP1699810A4
(en)
|
2003-12-17 |
2009-10-21 |
Elan Pharm Inc |
BETWEEN BETA IMMUNOGENIC PEPTIDE CONJUGATES PRODUCTION TECHNIQUES OF THESE CONJUGATES
|
BRPI0417744B8
(pt)
|
2003-12-17 |
2021-05-25 |
Wyeth Corp |
método para produzir um conjugado imunogênico, e,conjugado imunogênico
|
US7968565B2
(en)
*
|
2004-03-15 |
2011-06-28 |
Sunesis Pharmaceuticals, Inc. |
Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
US7674456B2
(en)
*
|
2004-06-14 |
2010-03-09 |
Charles Wiseman |
Breast cancer cell lines and uses thereof
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
US20060036080A1
(en)
*
|
2004-07-16 |
2006-02-16 |
Bossard Mary J |
Conjugates of GM-CSF moiety and a polymer
|
US20060062764A1
(en)
*
|
2004-08-25 |
2006-03-23 |
Seshidar-Reddy Police |
Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
|
US20060057127A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Pocheng Liu |
Cytokine-expressing cellular vaccines for treatment of prostate cancer
|
EP2298341A3
(en)
|
2004-10-21 |
2011-07-13 |
Wyeth LLC |
Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
|
WO2006049599A1
(en)
*
|
2004-10-28 |
2006-05-11 |
The General Hospital Corporation |
Methods of detection and therapy for atheromatous plaques using immune modulation
|
WO2006050058A2
(en)
*
|
2004-10-28 |
2006-05-11 |
The General Hospital Corporation |
Methods of detection and therapy of inflamed tissues using immune modulation
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
AU2007241023B2
(en)
|
2006-03-30 |
2013-11-28 |
University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
US7919079B2
(en)
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
CN104027333B
(zh)
*
|
2006-06-12 |
2017-05-17 |
逊尼希思制药公司 |
治疗癌症的化合物和组合物
|
PL2495307T3
(pl)
|
2006-07-13 |
2018-07-31 |
Wyeth Llc |
Wytwarzanie czynnika krzepliwości krwi IX o polepszonym wzorze glikozylacji
|
JP5401319B2
(ja)
*
|
2006-11-03 |
2014-01-29 |
ワイス・エルエルシー |
細胞培養における解糖阻害物質
|
WO2008140571A2
(en)
*
|
2006-11-15 |
2008-11-20 |
Functional Genetics, Inc. |
Methods and compositions for treating influenza
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
JP5586235B2
(ja)
|
2007-03-02 |
2014-09-10 |
ワイス・エルエルシー |
ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用
|
EP2117579A4
(en)
*
|
2007-03-07 |
2011-08-24 |
Mayo Foundation |
TREATMENT OF CANCER USING A GRANULOCYTIC MACROPHAGE COLONY STIMULATING FACTOR
|
US20100255513A1
(en)
*
|
2007-03-30 |
2010-10-07 |
Denson Lee A |
Serological markers of inflammatory bowel disease phenotype and disease progression
|
US20080267935A1
(en)
*
|
2007-04-06 |
2008-10-30 |
Cell Genesys, Inc. |
AraC in combination with a cytokine-secreting cell and methods of use thereof
|
WO2009014708A2
(en)
*
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
US8425897B2
(en)
*
|
2007-08-30 |
2013-04-23 |
Immutep S.A. |
Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
|
KR20110004354A
(ko)
*
|
2007-12-21 |
2011-01-13 |
와이어쓰 엘엘씨 |
유전자 변형된 약독화 수포성 구내염 바이러스, 이의 조성물 및 사용 방법
|
KR20110031343A
(ko)
|
2008-06-20 |
2011-03-25 |
와이어쓰 엘엘씨 |
베타-용혈성 스트렙토코커스 균주로부터 유래된 orf1358을 사용하는 조성물 및 방법
|
AR074273A1
(es)
*
|
2008-11-05 |
2011-01-05 |
Wyeth Corp |
Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
|
KR101774062B1
(ko)
|
2009-06-22 |
2017-09-01 |
와이어쓰 엘엘씨 |
황색포도상구균 혈청형 5 및 8 협막 다당류 접합체 면역원성 조성물 및 이의 제조 방법
|
SA110310528B1
(ar)
|
2009-06-22 |
2014-07-02 |
Wyeth Llc |
التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
|
EP2335730A1
(en)
|
2009-12-18 |
2011-06-22 |
Deutsches Krebsforschungszentrum |
Fusion polypeptides and their use for prevention and treatment of cancer
|
HUE033071T2
(hu)
|
2010-06-04 |
2017-11-28 |
Wyeth Llc |
Vakcinakészítmények
|
DK3831406T3
(da)
|
2010-08-23 |
2024-06-17 |
Wyeth Llc |
Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
|
CA2809758C
(en)
|
2010-09-10 |
2021-07-13 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
HUE047263T2
(hu)
|
2010-12-22 |
2020-04-28 |
Wyeth Llc |
Staphylococcus aureus antigének stabil immunogén készítményei
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
BR112014021658A2
(pt)
|
2012-03-09 |
2017-07-11 |
Pfizer |
composições de neisseria meningitidis e métodos das mesmas
|
US20150190499A1
(en)
|
2012-07-19 |
2015-07-09 |
Zoetis Llc |
Bovine influenza c virus compositions
|
AU2013295770A1
(en)
|
2012-07-27 |
2015-01-29 |
Zoetis Services Llc |
Tick toxin compositions
|
CA2943263C
(en)
|
2012-12-20 |
2018-12-04 |
Pfizer Inc. |
Glycoconjugation process
|
US9724366B2
(en)
|
2012-12-30 |
2017-08-08 |
Carmel-Haifa University Economic Corporation Ltd |
CD11 B[low] macrophages and conditioned media thereof for treating cancer and/or fibrosis
|
WO2014136064A2
(en)
|
2013-03-08 |
2014-09-12 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
WO2014151401A1
(en)
|
2013-03-15 |
2014-09-25 |
Zoetis Llc |
CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
EP4098276A1
(en)
|
2013-09-08 |
2022-12-07 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
WO2016130569A1
(en)
|
2015-02-09 |
2016-08-18 |
Mj Biologics, Inc. |
A composition comprising pedv antigens and methods for making and using the composition
|
CN106535930A
(zh)
|
2014-03-11 |
2017-03-22 |
明尼苏达大学董事会 |
猪流行性腹泻病毒疫苗及其使用方法
|
GB201500374D0
(en)
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
BR112017017460A2
(pt)
|
2015-02-19 |
2018-04-10 |
Pfizer Inc. |
composições de neisseria meningitidis e métodos das mesmas
|
CN107466326B
(zh)
|
2015-03-12 |
2021-10-15 |
硕腾服务有限责任公司 |
溶血素方法和组合物
|
IL297740A
(en)
|
2015-05-04 |
2022-12-01 |
Pfizer |
Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses
|
EP3334454B1
(en)
|
2015-08-14 |
2022-10-19 |
Zoetis Services LLC |
Mycoplasma bovis compositions
|
WO2017123201A1
(en)
|
2016-01-11 |
2017-07-20 |
Zoetis Services Llc |
Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
|
US11033615B2
(en)
|
2016-05-31 |
2021-06-15 |
The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland |
Zika virus vaccine and methods of production
|
BR112019006900A2
(pt)
|
2016-10-05 |
2019-07-02 |
Zoetis Services Llc |
métodos de liofilização que proporcionam protozoários desidratados estáveis para o uso como potentes vacinas vivas
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
WO2018142280A2
(en)
|
2017-01-31 |
2018-08-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
GB201703529D0
(en)
|
2017-03-06 |
2017-04-19 |
Cambridge Entpr Ltd |
Vaccine composition
|
US20230146256A1
(en)
|
2020-04-17 |
2023-05-11 |
Regents Of The University Of Minnesota |
SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
|
WO2022043855A1
(en)
|
2020-08-26 |
2022-03-03 |
Pfizer Inc. |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
EP4241791A1
(en)
|
2022-03-07 |
2023-09-13 |
InnaTher Gene Therapy S.à.r.l. |
Combined gene and radio therapy for the treatment of cancer
|
EP4241790A1
(en)
|
2022-03-07 |
2023-09-13 |
InnaTher Gene Therapy S.à.r.l. |
Expression system for the treatment of cancer
|
WO2024069420A2
(en)
|
2022-09-29 |
2024-04-04 |
Pfizer Inc. |
Immunogenic compositions comprising an rsv f protein trimer
|